Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A | P35348 | 7/20 | 0.39 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.39 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.38 |
| ▸ | METTL3 | Q86U44 | 1/20 | 0.38 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.38 |
| ▸ | PDE10A | Q9Y233 | 8/20 | 0.37 |
| ▸ | HTR5A | P47898 | 1/20 | 0.37 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.35 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Glycolic Acid SCHEMBL28376580 | 0.82 | LTA4H (0.38) | ADRA1AADRA1DPRMT5METTL3WDR77 | |
| Glycolic Acid SCHEMBL28707780 | 0.80 | PRMT5 (0.37) | ADRA1AADRA1DPRMT5METTL3WDR77 | |
| SCHEMBL29558081 | 0.79 | ADRA1A (0.38) | ADRA1AADRA1DPRMT5METTL3WDR77 | |
| SCHEMBL30915761 | 0.78 | KDM4E (0.46) | ADRA1AADRA1DHTR5AADRA2A | |
| SCHEMBL9342154 | 0.78 | KDM4E (0.46) | ADRA1AADRA1DHTR5AADRA2A | |
| Hydrochloric Acid SCHEMBL8985222 | 0.76 | KDM4E (0.45) | ADRA1AADRA1DHTR5AADRA2A | |
| SCHEMBL24493549 | 0.76 | KDM4E (0.47) | ADRA1A | |
| SCHEMBL25124475 | 0.75 | HTR5A (0.37) | ADRA1AADRA1DPRMT5METTL3WDR77 | |
| Hydrochloric Acid SCHEMBL16340766 | 0.75 | KDM4E (0.46) | ADRA1A | |
| SCHEMBL16340873 | 0.75 | PDE10A (0.40) | PDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12630562-B2 | Piperidylurea compounds and methods of use thereof | ARCUS BIOSCIENCES, INC. (US) | 2026-05-19 | — | — | US | disclosed |
| US-20260042777-A1 | PIPERIDYLUREA COMPOUNDS AND METHODS OF USE THEREOF | ARCUS BIOSCIENCES, INC. (US) | 2026-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12630562-B2 | Piperidylurea compounds and methods of use thereof | CLIC1, HCCS, CNR1 | ADRA1A 632/4885ADRA1D 449/4885PRMT5 1362/4885 |
| US-20260042777-A1 | PIPERIDYLUREA COMPOUNDS AND METHODS OF USE THEREOF | CBR1, CLIC1, RER1 | ADRA1A 722/4885ADRA1D 535/4885PRMT5 1125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.